Prescription medicine
Rimegepant Brand names: Nurtec; first approved as Nurtec Odt
Rimegepant (Nurtec) is a prescription medicine with an FDA approval on record since 2020. No generic is listed; pharmacies paid $128.67 per Nurtec ODT 75 mg tablet in the October 7, 2026 NADAC survey.
- No generic listed
Check it at the source: the rimegepant FDA label on DailyMed (effective June 4, 2026, Pfizer Laboratories Div Pfizer Inc); the NDA 212728 record on Drugs@FDA; every rimegepant label on DailyMed.
Highlights of the record
FDA label of June 4, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageNURTEC ODT is a calcitonin gene-related peptide receptor antagonist indicated for the:
acute treatment of migraine with or without aura in adults ( 1.1 )
preventive treatment of episodic migraine in adults ( 1.2 ) 1.1 Acute Treatment of Migraine NURTEC ODT is indicated for the acute treatment of migraine with or without aura in adults.
Forms and strengths
- 75 mg
Orally disintegrating tablet.
On the market
- Earliest approval on file
- February 27, 2020 Nurtec Odt, Pfizer; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 2 of which 0 under generic applications, 2 under brand applications, repackagers included
- Last listed patent
- March 25, 2039 Nurtec ODT tablets; not a generic launch date
Supply and safety
- Pharmacy cost (NADAC)
- $128.67 per tablet Nurtec ODT 75 mg tablet
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- 1 since 2021 0 Class I among all firms' recalls; latest March 15, 2021
- FAERS reports
- 12,599 through July 30, 2026
What is rimegepant used for?
From the label: indications and usageNURTEC ODT is a calcitonin gene-related peptide receptor antagonist indicated for the:
acute treatment of migraine with or without aura in adults ( 1.1 )
preventive treatment of episodic migraine in adults ( 1.2 ) 1.1 Acute Treatment of Migraine NURTEC ODT is indicated for the acute treatment of migraine with or without aura in adults. 1.2 Preventive Treatment of Episodic Migraine NURTEC ODT is indicated for the preventive treatment of episodic migraine in adults.
Conditions named in the indications of rimegepant's FDA labels, with every medicine labeled for each:
FDA pharmacologic class: Calcitonin Gene-related Peptide Receptor Antagonist.
Source: FDA drug label (NURTEC ODT), Pfizer Laboratories Div Pfizer Inc, effective June 4, 2026 (SPL set 9ef08e09-1098-35cc-e053-2a95a90a3e1d), via openFDA; the full label on DailyMed
Is there a generic for rimegepant (Nurtec)?
No generic rimegepant is approved (Drugs@FDA, October 8, 2026). Drugs@FDA also holds 1 tentative approval: the FDA found the generic approvable, but patents or exclusivity keep it from final approval for now.
The Orange Book lists 3 patents for Nurtec ODT tablets: the compound patent runs to February 27, 2034, and the last listed entry to March 25, 2039. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.
- 2020 earliest approval on file
- 2039 last listed patent
- red ticks recalls
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for rimegepant (Nurtec)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $128.67 per Nurtec ODT 75 mg tablet, up 4% from $123.17 on October 8, 2025. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Nurtec ODT 75 mg tablet (brand)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Nurtec ODT 75 mg tablet | Brand | $128.67 per tablet | $3,860.09 | +4% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
Has rimegepant been recalled?
The FDA's Enforcement Report lists 1 recall naming rimegepant since 2021: 0 Class I (the most serious), 1 Class II, 0 Class III; 0 still ongoing. A recall names products and lots, not every product of the medicine.
| Started | Class | Company | Reason |
|---|---|---|---|
| March 15, 2021 | Class II | Cardinal Health Inc. | CGMP Deviations: Intermittent exposure to temperature excursion during storage. |
Source: FDA Enforcement Report (drug recalls) via openFDA, through October 8, 2026
What does the rimegepant label say about other medicines?
The rimegepant label names 4 other medicines in its interaction, contraindication or warning sections. The labels of 1 other medicine name rimegepant. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Amiodarone | drug interactions | Concomitant administration of NURTEC ODT with potent inhibitors of P-gp (e.g., amiodarone, cyclosporine, lapatinib, quinidine, ranolazine) may result in increased exposure of rimegepant. |
| Cyclosporine | drug interactions | Concomitant administration of NURTEC ODT with potent inhibitors of P-gp (e.g., amiodarone, cyclosporine, lapatinib, quinidine, ranolazine) may result in increased exposure of rimegepant. |
| Quinidine | drug interactions | Concomitant administration of NURTEC ODT with potent inhibitors of P-gp (e.g., amiodarone, cyclosporine, lapatinib, quinidine, ranolazine) may result in increased exposure of rimegepant. |
| Ranolazine | drug interactions | Concomitant administration of NURTEC ODT with potent inhibitors of P-gp (e.g., amiodarone, cyclosporine, lapatinib, quinidine, ranolazine) may result in increased exposure of rimegepant. |
Other labels that name rimegepant
Source: FDA drug label (NURTEC ODT), Pfizer Laboratories Div Pfizer Inc, effective June 4, 2026 (SPL set 9ef08e09-1098-35cc-e053-2a95a90a3e1d), via openFDA; the full label on DailyMed
What do FAERS reports show for rimegepant?
The FDA Adverse Event Reporting System holds 12,599 reports that list rimegepant among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 109 are coded as a death and 708 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is. Reports rose sharply in 2022 (3,581, against a median of 675 a year): FAERS counts follow reporting, which news, litigation and label changes can drive, not how often a reaction happens.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as rimegepant?
12 other medicines are given the same way (oral) and in the same FDA class as rimegepant or labeled mainly for the same use (migraine), the same class first. Migraine lists all 27 medicines labeled for it, by any route. The first 8 are below. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (oral) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Ubrogepant | Migraine | none listed | $109.11 per tablet 100 mg tablet | No current entry |
| Atogepant | Migraine | none listed | $38.36 per tablet 10 mg tablet | No current entry |
| Sumatriptan | Migraine | 22 labelers | $0.302 per tablet 50 mg tablet | No current entry |
| Rizatriptan | Migraine | 25 labelers | $0.335 per tablet 10 mg tablet | No current entry |
| Zolmitriptan | Migraine | 18 labelers | $1.02 per tablet 2.5 mg tablet | No current entry |
| Eletriptan | Migraine | 10 labelers | $1.75 per tablet 40 mg tablet | No current entry |
| Naratriptan | Migraine | 4 labelers | $1.08 per tablet 2.5 mg tablet | No current entry |
| Almotriptan | Migraine | 3 labelers | $16.86 per tablet 12.5 mg tablet | No current entry |
Every medicine labeled for the same conditions as rimegepant
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
What next?
- Alternatives to rimegepant
- 12 medicines for the same use
- Other calcitonin gene-related peptide receptor antagonists
- the pharmacologic class, with prices and generics
- Rimegepant side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other